Corporate Governance - All resolutions proposed at Novo Resources Corp.'s annual general meeting were approved, including the election of all director nominees [1] - Voting results for director nominees showed high approval rates, with Karen O'Neill receiving 99.063% of votes in favor [1] Corporate Developments - Novo has released a new corporate presentation available on its website [2] - The company has formed a lithium joint venture with SQM in the Pilbara, enhancing shareholder exposure to battery metals [6] Project Portfolio - Novo's key project area is the Egina Gold Camp, where a joint venture with Northern Star Resources Limited involves A$25 million exploration expenditure for a 50% interest in the Becher Project [5] - The company has strengthened its exploration portfolio by adding the TechGen John Bull Gold Project and the Manhattan Tibooburra Gold Project, both showing potential for significant gold discoveries [7] - Novo's land package covers approximately 5,500 square kilometers in the Pilbara region and includes the 22 square kilometer Belltopper project in Victoria [4]

VONORE, Tenn., June 24, 2025 (GLOBE NEWSWIRE) -- MasterCraft Boat Company, a subsidiary of MasterCraft Boat Holdings, Inc (NASDAQ: MCFT) and the best-selling towboat brand, is proud to return as an official sponsor of the 2025 American Century Championship (ACC) in Lake Tahoe, beginning July 9. Building on its six years of sponsorship, MasterCraft will showcase its premium towboat lineup – including the recently redesigned flagship models, XStar 23 and XStar 25 while leading several high-impact activations ...

CHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its entry into the U.S. market and the launch of U.S.-based manufacturing through a strategic agreement with DolCas Biotech LLC (“DolCas”), a ...

Paris, 24 June 2025 Capitalised terms used herein shall have the meaning specified for such terms in the Caisse Française de Financement Local base prospectus to the €75,000,000,000 Euro Medium Term Note Programme dated 10 June 2025 (the “Base Prospectus”). Caisse Française de Financement Local has decided to issue on 26 June 2025 – Euro 10,000,000 Fixed Rate Obligations Foncières due 26 June 2048. The Base Prospectus dated 10 June 2025 approved by the Autorité des Marchés Financiers is available on the we ...

Core Insights - Sify Technologies Limited has appointed Dr. Ram Sewak Sharma as a new Director on its Board, bringing extensive experience in ICT and administrative reforms [1][5]. Company Overview - Sify Technologies is recognized as India's leading Digital ICT solutions provider, offering services in Data Center, Cloud, Networks, Security, and Digital services [1][7]. - The company has received multiple Golden Peacock awards for Corporate Governance, highlighting its commitment to ethical business practices [7]. Leadership and Expertise - Dr. Sharma has over four decades of experience in the Indian Administrative Service and has played a significant role in shaping India's ICT policies [2][4]. - He was the founding Director General of the Unique Identification Authority of India (UIDAI), where he was instrumental in launching Aadhaar, the world's largest biometric identity system [3][4]. - His background includes leadership roles in the telecom industry, including Chairman of the Telecom Regulatory Authority of India (TRAI) [4]. Strategic Vision - The Chairman of Sify, Mr. Raju Vegesna, expressed confidence that Dr. Sharma's experience will be a valuable asset as the company aims to strengthen its leadership position across various business segments [5]. - Dr. Sharma emphasized the importance of technology as a catalyst for implementing large-scale social welfare measures, which aligns with Sify's mission to scale its services [6]. Market Presence - Sify serves over 10,000 businesses across various sectors, leveraging its infrastructure of state-of-the-art Data Centers and the largest MPLS network in India [8][9]. - The company has a significant international presence, operating in North America, the United Kingdom, UAE, and Singapore, catering to a diverse clientele [9].

Core Points - Fingerprint Cards AB held its Annual General Meeting on June 24, 2025, in Stockholm, where several key resolutions were passed [1] Dividend - The Meeting resolved that no dividend be paid [2] Board of Directors and Auditors - The directors of the Board and the managing director were discharged from liability for the period from January 1 to December 31, 2024 [3] - Christian Lagerling and Adam Philpott were re-elected as Board Members, while John Lord and Carl Johan Grandinson were newly elected [3] - Christian Lagerling was re-elected as Chairman of the Board of Directors [3] Board Remuneration - Board remuneration was set at SEK 675,000 for the Chairman and SEK 295,000 for each other Board Member, with no remuneration for employed Board members [4] - The adjusted Board remuneration is expected to result in significant cost savings for the Company [4] Auditors - BDO Mälardalen AB was re-elected as auditor, with Johan Pharmanson as Auditor-in-Charge, until the end of the next Annual General Meeting [5] - Remuneration for auditors will be paid according to approved invoices [5] Remuneration Report - The Meeting approved the Board of Directors' remuneration report for 2024 in accordance with Swedish Companies Act [6] Share Repurchase and Transfer Authorization - The Board was authorized to repurchase up to 10% of the total number of outstanding class B shares until the next Annual General Meeting [7] - The Board was also authorized to transfer class B shares, deviating from shareholders' preferential rights [7] Amendment of Articles and Reverse Share Split - The Meeting approved amendments to the articles of association to enable a reverse share split, consolidating 2,000 existing shares into one [8] - Post-split, the number of shares will decrease from 15,175,375,766 to 7,587,687 shares, and votes will decrease from 15,246,250,766 to 7,623,120 [8] - The Board was authorized to determine the record date for the reverse share split [8] New Share Issue Authorization - The Board was authorized to issue new class B shares, warrants, and/or convertibles up to 20% of the total number of outstanding shares until the next Annual General Meeting [11] Long-term Incentive Programs - The Meeting approved an Employee Stock Option Program 2025/2028, allowing for the issuance of up to 265,595 options for B-shares [12] - The program allows subscription for B-shares at a price corresponding to 150% of the volume-weighted average price during the first ten trading days following the record date for the reverse share split [12] - A separate Employee Stock Option Program 2025/2029 was also approved for the Board, allowing for up to 113,815 options [13]

Core Insights - Hoth Therapeutics' investigational candidate HT-001 achieved a 100% response rate in at least one primary efficacy endpoint in its ongoing Phase 2a clinical study for EGFR inhibitor-induced skin toxicities [2][7] - The company will host a Key Opinion Leader event to discuss the interim results and potential impact of HT-001 on supportive care standards for oncology patients [1] Clinical Trial Highlights - The Phase 2a trial (CLEER-001) demonstrated that 100% of enrolled patients achieved at least one primary endpoint of clinical dermatologic improvement [7][8] - Over 65% of patients reported reductions in pain and pruritus, with 0% requiring dose reduction or discontinuation of their EGFR inhibitor therapy [7][8] - HT-001 is a once-daily topical gel that targets neuroinflammatory pathways without causing immunosuppression or systemic toxicity [4] Mechanism of Action - HT-001 is formulated with an FDA-approved neurokinin-1 receptor antagonist (NK1RA) that mitigates inflammatory pathways triggered by EGFR inhibition, particularly those driven by Substance P [4][5] - Preclinical data showed significant reductions in dermatitis and alopecia severity, as well as inflammatory markers in rat models co-treated with erlotinib [5][9] Regulatory and Development Pathway - HT-001 is being advanced under the 505(b)(2) regulatory pathway, which allows the use of existing safety data to expedite development [10] - The company is currently planning a Phase 2b/3 trial following the ongoing Phase 2a trial [13]

Tim Scoffham Tim Scoffham, CEO of Sports.com Media LTD and Lottery.com International LTD. FORT WORTH, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Lottery.com Inc. (NASDAQ: LTRY, LTRYW) (“Lottery.com” or “the Company”), a leading technology company transforming the intersection of gaming, sports and entertainment, today announced the appointment of Tim Scoffham as Chief Executive Officer of Sports.com Media Group Limited (“Sports.com Media”) and Lottery.com International Limited (“Lottery.com International” ...

Celebrating the bold leaders shaping the future through the world’s most ground-breaking companiesNEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) announced that Rohit Kapoor, chairman and chief executive officer of EXL, was named an Entrepreneur Of The Year 2025 New York Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies. For 40 years, EY US has celebrated ambitious entrepreneurs who are transformin ...

Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell ActivationLAS VEGAS , June 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives, Inc. (OTC Pink: BDPT), an innovator in nutraceutical and wellness science, today announces the upcoming national release of Pawpa™ Regen, a proprietary canine supplement that supports natural stem cell activation and regenerative healing in aging dogs. After a successful limited market release earlier this year, Pawpa™ Regen officially launches nati ...